Skip to main content

Table 1 Demographic data of patients taking sodium channel blocking antiseizure medications

From: Response to Sodium Channel blocking Antiseizure medications and coding polymorphisms of Sodium Channel genes in Taiwanese epilepsy patients

  All (n = 200) Response (n = 109) Not seizure-free (n = 91) p
Onset age (year) 16.0 (8.0–24) 17.5 (10.0–26.0) 12.8 (5.5–20) 0.001
Male 100 (50.0) 54 (49.5) 46 (50.5) reference
Female 100 (50.0) 55 (50.5) 45 (49.5) 0.887
Seizure type
 Focal 121 (60.5) 62 (56.9) 59 (64.8) 0.265
 Generalized 51 (25.5) 24 (22.0) 27 (29.7)  
 Unspecified 28 (14.0) 23 (21.1) 5 (5.5)  
Etiology
 Structural 38 (19.0) 17 (15.6) 21 (23.1) 0.760
 CNS infection 12 (6.0) 6 (5.5) 6 (6.6)  
 Genetic 4 (2.0) 1 (0.9) 3 (3.3)  
 Autoimmune 4 (2.0) 1 (0.9) 3 (3.3)  
 Unknown 142 (71.0) 84 (77.1) 58 (63.7)  
Number of ASMs
 1 65 (32.5) 58 (53.2) 7 (7.7)  
 2 61 (30.5) 37 (33.9) 24 (26.4)  
 3 47 (23.5) 12 (11.0) 35 (38.5)  
 4 16 (8.0) 2 (1.8) 14 (15.4)  
 5 9 (4.5) 0 (0.0) 9 (9.9)  
 6 2 (1.0) 0 (0.0) 2 (2.2)  
Concurrent ASMs
 Carbamazepine 49 26 23  
 Clobazam 11 2 9  
 Gabapentin 2 0 2  
 Lacosamide 3 0 3  
 Lamotrigine 70 35 35  
 Levetiracetam 80 26 54  
 Oxcarbazepine 22 7 15  
 Perampanel 11 0 11  
 Phenobarbital 19 1 12  
 Phenytoin 40 22 18  
 Pregabalin 3 0 3  
 Topiramate 41 13 28  
 Valproic acid 72 40 32  
 Vigabatrin 4 0 4  
 Zonisamide 28 4 24  
  1. Continuous variables were presented as median (interquartile range)
  2. Categorical variables were presented as n (%)
  3. Abbreviations: CNS central nervous system, ASM antiseizure medication